# SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

> **NCT02986867** · NA · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Urothelial Carcinoma
- Melanoma
- Cervical Carcinoma in Situ

## Interventions

- **RADIATION:** SAbR Treatment of Lesions

## Key facts

- **NCT ID:** NCT02986867
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-03-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02986867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02986867, "SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02986867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*